metformin hydrochloride; sitagliptin - Profile

What are the generic drug sources for metformin hydrochloride; sitagliptin and what is the scope of freedom to operate?

Metformin hydrochloride; sitagliptin is the generic ingredient in five branded drugs marketed by Zydus Lifesciences, Msd Sub Merck, Ph Health, Apotex, and Sandoz, and is included in seven NDAs. There are two patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Summary for metformin hydrochloride; sitagliptin

US Patents:	2
Tradenames:	5
Applicants:	5
NDAs:	7

US Patents and Regulatory Information for metformin hydrochloride; sitagliptin

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Zydus Lifesciences	ZITUVIMET XR	metformin hydrochloride; sitagliptin	TABLET, EXTENDED RELEASE;ORAL	216778-002	Jul 18, 2024		RX	Yes	No
Zydus Lifesciences	ZITUVIMET XR	metformin hydrochloride; sitagliptin	TABLET, EXTENDED RELEASE;ORAL	216778-003	Jul 18, 2024		RX	Yes	Yes
Zydus Lifesciences	ZITUVIMET XR	metformin hydrochloride; sitagliptin	TABLET, EXTENDED RELEASE;ORAL	216778-001	Jul 18, 2024		RX	Yes	No
Zydus Lifesciences	ZITUVIMET	metformin hydrochloride; sitagliptin	TABLET;ORAL	216743-002	Nov 3, 2023		RX	Yes	Yes
Zydus Lifesciences	ZITUVIMET	metformin hydrochloride; sitagliptin	TABLET;ORAL	216743-001	Nov 3, 2023		RX	Yes	No

EU/EMA Drug Approvals for metformin hydrochloride; sitagliptin

Company	Drugname	Inn	Product Number / Indication	Status	Generic	Biosimilar	Orphan	Marketing Authorisation	Marketing Refusal
Merck Sharp & Dohme B.V.	Ristfor	sitagliptin, metformin hydrochloride	EMEA/H/C/001235For patients with type-2 diabetes mellitus:Ristfor is indicated as an adjunct to diet and exercise to improve glycaemic control in patients inadequately controlled on their maximal tolerated dose of metformin alone or those already being treated with the combination of sitagliptin and metformin.Ristfor is indicated in combination with a sulphonylurea (i.e. triple combination therapy) as an adjunct to diet and exercise in patients inadequately controlled on their maximal tolerated dose of metformin and a sulphonylurea.Ristfor is indicated as triple combination therapy with a peroxisome proliferator-activated-receptor-gamma (PPARγ) agonist (i.e. a thiazolidinedione) as an adjunct to diet and exercise in patients inadequately controlled on their maximal tolerated dose of metformin and a PPARγ agonist.Ristfor is also indicated as add-on to insulin (i.e. triple combination therapy) as an adjunct to diet and exercise to improve glycaemic control in patients when stable dose of insulin and metformin alone do not provide adequate glycaemic control.	Authorised	no	no	no	2010-03-15
Accord Healthcare S.L.U.	Sitagliptin / Metformin hydrochloride Accord	sitagliptin, metformin hydrochloride	EMEA/H/C/005850For adult patients with type 2 diabetes mellitus:It is indicated as an adjunct to diet and exercise to improve glycaemic control in patients inadequately controlled on their maximal tolerated dose of metformin alone or those already being treated with the combination of sitagliptin and metformin.It is indicated in combination with a sulphonylurea (i.e., triple combination therapy) as an adjunct to diet and exercise in patients inadequately controlled on their maximal tolerated dose of metformin and a sulphonylurea.It is indicated as triple combination therapy with a peroxisome proliferator-activated receptor gamma (PPARγ) agonist (i.e., a thiazolidinedione) as an adjunct to diet and exercise in patients inadequately controlled on their maximal tolerated dose of metformin and a PPARγ agonist.It is also indicated as add-on to insulin (i.e., triple combination therapy) as an adjunct to diet and exercise to improve glycaemic control in patients when stable dose of insulin and metformin alone do not provide adequate glycaemic control.	Authorised	yes	no	no	2022-07-22
Sun Pharmaceutical Industries Europe B.V.	Sitagliptin / Metformin hydrochloride Sun	sitagliptin, metformin hydrochloride	EMEA/H/C/005778For adult patients with type 2 diabetes mellitus:Sitagliptin/Metformin hydrochloride SUN is indicated as an adjunct to diet and exercise to improve glycaemic control in patients inadequately controlled on their maximal tolerated dose of metformin alone or those already being treated with the combination of sitagliptin and metformin.Sitagliptin/Metformin hydrochloride SUN is indicated in combination with a sulphonylurea (i.e., triple combination therapy) as an adjunct to diet and exercise in patients inadequately controlled on their maximal tolerated dose of metformin and a sulphonylurea.Sitagliptin/Metformin hydrochloride SUN is indicated as triple combination therapy with a peroxisome proliferator-activated receptor gamma (PPARγ) agonist (i.e., a thiazolidinedione) as an adjunct to diet and exercise in patients inadequately controlled on their maximal tolerated dose of metformin and a PPARγ agonist.Sitagliptin/Metformin hydrochloride SUN is also indicated as add-on to insulin (i.e., triple combination therapy) as an adjunct to diet and exercise to improve glycaemic control in patients when stable dose of insulin and metformin alone do not provide adequate glycaemic control.	Authorised	yes	no	no	2023-03-31

Investment Scenario and Fundamentals Analysis for Metformin Hydrochloride and Sitagliptin

Last updated: February 26, 2026

Overview of Drugs

Metformin hydrochloride is a first-line oral medication for type 2 diabetes, primarily reducing hepatic glucose production. It has a generic market presence and is included in many combination therapies.

Sitagliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor used to improve glycemic control. It is marketed under the brand name Januvia and has faced patent expiration pressures but remains relevant through combinations and new indications.

---

Market Size and Growth Dynamics

Parameter	2022	Projected 2028	Compound Annual Growth Rate (CAGR)	Source
Type 2 diabetes global market	$50 billion	$70 billion	6.0%	[1]
Metformin market share	>70%	Stable	--	[2]
Sitagliptin market share	Significant	Declining post-patent	-1% to 0%	[3]

Note: The diabetes treatment market expands as global prevalence rises from approximately 537 million cases in 2021 to over 700 million in 2045 (IDF). The aging population and lifestyle factors drive the increase.

---

Fundamentals of Metformin Hydrochloride

Market Position and Competitive Landscape

• Generic dominance: Metformin is available as a generic, leading to low price points.

• Patent status: No active patents; manufacturing is commoditized.

• Pricing: Average wholesale price (AWP) around $0.02 per 500mg tablet.

• Regulatory aspects: Approved globally, including in the US, EU, and emerging markets; recent safety alerts regarding lactic acidosis have minimal impact on use.

Revenue Drivers and Risks

• Volume-driven sales: Large patient base and low price support high volume sales.

• Market penetration: Existing in most countries; primary therapy but facing increasing competition from newer agents like SGLT2 inhibitors.

• Innovation potential: Minimal; focus on combination formulations with other antidiabetics.

Investment Considerations

• Low profit margin: Due to commoditization.

• Stable cash flow: Strong due to volume sales.

• Growth prospects: Limited, heavily reliant on global diabetes prevalence.

---

Fundamentals of Sitagliptin

Market Position and Competition

• Patent expiration: In the US, patent expired in 2017; generics entered markets thereafter.

• Revenue decline: Post-patent, branded sales decreased approximately 40% by 2020.

• Pricing: Branded price around $3-4 per tablet; generics under $1.

• Market share: Dominated initially by Merck’s Januvia; new DPP-4 inhibitors and GLP-1 receptor agonists emerge as competitors.

Growth Drivers and Challenges

• Combination drugs: Sitagliptin increasingly sold as fixed-dose combinations (FDCs) with metformin, broadening use.

• New indications: Investigations into cardiovascular and renal benefits support second-line positioning.

• Market erosion: Competitive pressure from SGLT2 inhibitors (e.g., empagliflozin) and GLP-1 agonists (e.g., semaglutide).

Investment Outlook

• Revenue stability: Declines due to generic competition but benefits from combination formulations.

• Patent cliff impact: Significant downward pressure on branded sales.

• Innovation potential: Limited; focus on second-generation formulations and new therapeutic areas.

---

Regulatory and Patent Landscape

• Metformin: No active patents; manufacturing rights operate under patent expiry regimes. Regulatory hurdles mainly involve safety considerations.

• Sitagliptin: Patent expired in many major markets, but specific patent protection on formulations or combination products can extend revenue streams.

• Legal/IP extensions: Certain patents on formulations or methods may provide limited exclusivity.

---

Investment Risks and Opportunities

Risks

• Market saturation: Both drugs face commoditization, pressuring margins.

• Pricing pressure: Healthcare systems favor low-cost generics.

• Competitive shifts: Emergence of newer drug classes—SGLT2 inhibitors and GLP-1 analogs—reduces share for older agents.

Opportunities

• Emerging markets: Growing diabetes prevalence enhances demand.

• Combination therapies: Development of fixed-dose combinations sustains sales.

• Research pipeline: Potential new indications or formulations could extend lifecycle.

---

Key Takeaways

• Market outlook remains stable for metformin due to its low cost and wide adoption but offers limited growth prospects.

• Sitagliptin faces revenue decline in developed markets post-generic entry but maintains value through combination formulations and specified indications.

• Investment focus should be on portfolio diversification, emerging markets growth, and innovation in combination therapies rather than standalone sales.

---

Frequently Asked Questions

1. How does patent expiration impact the profitability of these drugs?

Patent expiration generally leads to revenue decline due to generic competition. For metformin, the commoditized nature results in minimal profit margins. Sitagliptin's branded sales decline sharply post-patent, though some revenue persists through patents on specific formulations.

2. Are there ongoing innovations for metformin to extend its lifecycle?

Research explores modified-release formulations and combination products. However, these do not significantly alter the fundamental market dynamics dominated by generics.

3. What is the outlook for combination therapies involving these drugs?

Fixed-dose combinations are gaining traction. They improve patient adherence and can maintain branded sales for certain formulations, offering moderate growth avenues.

4. How do regulatory issues affect these drugs?

Safety alerts (e.g., lactic acidosis concerns for metformin) have had limited long-term impact on use. Regulatory agencies require safety updates but do not threaten approval for these well-established drugs.

5. Which markets present the best investment opportunities?

Emerging markets see increasing demand driven by high diabetes prevalence. Manufacturing cost advantages and an expanding patient base make these regions attractive despite lower per-unit prices.

---

References

[1] International Diabetes Federation. (2022). IDF Diabetes Atlas.
[2] IMS Health. (2021). Global Diabetes Market Report.
[3] EvaluatePharma. (2022). Drug Market Performance Reports.

(End of analysis)